{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Marked induction after mRNA vaccination in tumors",
                    "line_ref": "L31"
                },
                {
                    "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
                    "line_ref": "L39"
                }
            ],
            "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
        },
        {
            "claim_id": "C02",
            "claim": "Interferon-associated antigen processing and presentation pathways increase.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "Broader antigen display after intratumoral mRNA vaccination",
                    "line_ref": "L28"
                },
                {
                    "quote": "Strong expansion of MHC-I-presented landscape",
                    "line_ref": "L29"
                }
            ],
            "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
        },
        {
            "claim_id": "C03",
            "claim": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
                    "line_ref": "L28"
                },
                {
                    "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
                    "line_ref": "L29"
                }
            ],
            "caveat": "Mouse model effects may not map one-to-one to all human tumors."
        },
        {
            "claim_id": "C04",
            "claim": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x",
                    "line_ref": "L32"
                },
                {
                    "quote": "Checkpoint axis became more targetable",
                    "line_ref": "L32"
                }
            ],
            "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
        },
        {
            "claim_id": "C05",
            "claim": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Vaccinated subgroup had improved survival under ICI treatment",
                    "line_ref": "L30"
                },
                {
                    "quote": "Increased immune infiltration with combination therapy",
                    "line_ref": "L33"
                }
            ],
            "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
        }
    ]
}